Loading...
Collegium announced record revenue for 2019, driven by Xtampza ER growth and the acquisition of the Nucynta Franchise. The company is guiding to profitability in 2020.
Delivered record revenue in 2019.
Achieved non-GAAP profitability for three consecutive quarters.
Xtampza ER revenue growth of 51% in 2019.
Xtampza ER Prescriptions Grew 49% in 2019.
Collegium reiterates its full-year 2020 financial guidance and anticipates a financially transformative year.
Analyze how earnings announcements historically affect stock price performance